Effect of Anti-interleukin 5 (IL5) Therapy on Sputum Cells and Cytokines

计划入组 22 人 · 首次发布于 2020 年 6 月 2 日

Nation-wide Health Resource Consumption and Costs Associated With Mepolizumab

计划入组 7,938 人 · 首次发布于 2020 年 9 月 16 日

Biomarkers of Response to Mepolizumab Treatment in Patients With Nasal Polyps With or Without Bronchial Asthma

计划入组 57 人 · 首次发布于 2023 年 2 月 1 日

Mepolizumab(Nucala)

Rx

Mepolizumab Biosimilar (Mabpharm)

Mepolizumab Biosimilar (DNARX)

NuCana

United Kingdom

Nucana, Inc.

United States

Zucara Therapeutics, Inc.

Canada

GSK's Depemokimab Shows Promise in Reducing Severe Asthma Exacerbations

GSK's Nucala (Mepolizumab) Shows Promise in COPD Treatment, Regulatory Submissions Underway

GSK's Nucala (Mepolizumab) Approved in China for Chronic Rhinosinusitis with Nasal Polyps